Patient disposition
| Modification . | All patients (N = 75) . | . | Aggressive B-NHL . | Indolent B-NHL . | |||
|---|---|---|---|---|---|---|---|
| CLL/SLL (n = 22) . | DLBCL (n = 26) . | MCL (n = 2) . | RT (n = 1) . | FL (n = 19) . | MZL (n = 5) . | ||
| Median treatment duration, (range), mo | 7.4 (0.3-52.7) | 11 (2.0-40.0) | 2 (0.3-52.7) | 1.5 (1.0-2.0) | 11 | 7 (1.0-44.0) | 18 (5.0-41.0) |
| On study | 8 (11) | 3 (14) | 2 (8) | 0 (0) | 0 (0) | 2 (11) | 1 (20) |
| No modifications | 27 (36) | 0 | 16 (62) | 1 (50) | 0 (0) | 8 (42) | 2 (40) |
| Dose reduction of umbralisib | 11 (15) | 5 (23) | 1 (4) | 0 (0) | 0 (0) | 3 (16) | 2 (40) |
| Temporary treatment holds | 0 (0) | ||||||
| Temporary umbralisib hold | 29 (39) | 12 (55) | 4 (15) | 0 (0) | 0 (0) | 10 (53) | 3 (60) |
| Temporary ublituximab hold | 31 (41) | 17 (77) | 3 (12) | 1 (50) | 1 (100) | 6 (32) | 3 (60) |
| Discontinued treatment | 67 (89) | 19 (86) | 24 (92) | 2 (100) | 1 (100) | 17 (89) | 4 (80) |
| Disease progression | 44 (59) | 14 (64) | 17 (65) | 1 (50) | 1 (100) | 9 (47) | 2 (40) |
| Adverse event | 10 (13) | 1 (5) | 2 (8) | 0 (0) | 0 (0) | 5 (26) | 2 (40) |
| In CR or pursuing SCT* | 3 (4) | 1 (5) | 1 (4) | 0 (0) | 0 (0) | 1 (5) | 0 (0) |
| Withdrawn consent/investigator discretion | 7 (9) | 1 (5) | 3 (12) | 1 (50) | 0 (0) | 2 (11) | 0 (0) |
| Other | 3 (4) | 2 (9) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Modification . | All patients (N = 75) . | . | Aggressive B-NHL . | Indolent B-NHL . | |||
|---|---|---|---|---|---|---|---|
| CLL/SLL (n = 22) . | DLBCL (n = 26) . | MCL (n = 2) . | RT (n = 1) . | FL (n = 19) . | MZL (n = 5) . | ||
| Median treatment duration, (range), mo | 7.4 (0.3-52.7) | 11 (2.0-40.0) | 2 (0.3-52.7) | 1.5 (1.0-2.0) | 11 | 7 (1.0-44.0) | 18 (5.0-41.0) |
| On study | 8 (11) | 3 (14) | 2 (8) | 0 (0) | 0 (0) | 2 (11) | 1 (20) |
| No modifications | 27 (36) | 0 | 16 (62) | 1 (50) | 0 (0) | 8 (42) | 2 (40) |
| Dose reduction of umbralisib | 11 (15) | 5 (23) | 1 (4) | 0 (0) | 0 (0) | 3 (16) | 2 (40) |
| Temporary treatment holds | 0 (0) | ||||||
| Temporary umbralisib hold | 29 (39) | 12 (55) | 4 (15) | 0 (0) | 0 (0) | 10 (53) | 3 (60) |
| Temporary ublituximab hold | 31 (41) | 17 (77) | 3 (12) | 1 (50) | 1 (100) | 6 (32) | 3 (60) |
| Discontinued treatment | 67 (89) | 19 (86) | 24 (92) | 2 (100) | 1 (100) | 17 (89) | 4 (80) |
| Disease progression | 44 (59) | 14 (64) | 17 (65) | 1 (50) | 1 (100) | 9 (47) | 2 (40) |
| Adverse event | 10 (13) | 1 (5) | 2 (8) | 0 (0) | 0 (0) | 5 (26) | 2 (40) |
| In CR or pursuing SCT* | 3 (4) | 1 (5) | 1 (4) | 0 (0) | 0 (0) | 1 (5) | 0 (0) |
| Withdrawn consent/investigator discretion | 7 (9) | 1 (5) | 3 (12) | 1 (50) | 0 (0) | 2 (11) | 0 (0) |
| Other | 3 (4) | 2 (9) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Data are presented as n (%) unless otherwise indicated.
One patient achieved a CR and chose to come off treatment, and 2 patients discontinued treatment to pursue stem cell transplant (SCT).